There is emerging understanding that coronavirus disease-19 (COVID-19) induced respiratory complications appear to have a distinct pattern that differs from typical adult respiratory distress syndrome (ARDS). It is characterised by a dissociation between relatively well-preserved lung mechanics and the severity of hypoxemia [@b0005]. A possible explanation for the severe hypoxemia occurring in compliant lungs, is the loss of lung perfusion regulation and hypoxic vasoconstriction. Coagulation dysfunction also appears to be common in severe COVID-19 [@b0010], [@b0015], with fatal cases exhibiting diffuse microvascular thrombosis, suggesting a thrombogenic microangiopathy [@b0020].

It is becoming increasingly recognised, therefore, that endothelial damage and pulmonary microvascular thrombosis are central to the clinical severity of COVID-19 [@b0005], [@b0010], [@b0020]. Endothelial access by the virus is mediated via the protein angiotensin-converting enzyme 2 (ACE2), which is highly expressed on vascular tissue. Replication of virus within the host cell can cause direct cellular damage and release of pro-inflammatory signals. Angiotensin converting enzyme-2 (ACE-2) consumption by viral entry would be predicted to increase local angiotensin-II concentration, contributing to vasoconstriction, endothelial activation, and pro-inflammatory cytokine release -- inducing further alveolar epithelial and vascular endothelial cell damage [@b0010], [@b0015]. Endothelial cell involvement may then spread across vascular beds of different organs [@b0020].

Both diabetes and ethnicity appear to be additional risk factors emerging in clinical sequelae of the COVID-19 pandemic. Within the hospitalised COVID-19 population, individuals with diabetes are over-represented [@b0025], [@b0030]. A systematic review reported a significant association between diabetes and COVID-19 infection severity (Odds ratio 2.67, 95% CI 1.91--3.74) [@b0035]. Subsequent data from China estimated mortality rates near 10% in diabetes, from a sample of 72,314 confirmed cases [@b0040]. The most recent publication, comprising 7336 patients, showed the risk of fatal outcome from COVID-19 was up to 50% higher in patients with diabetes [@b0030]. Furthermore, well-controlled blood glucose was associated with lower hospital mortality than poorly controlled glucose (hazard ratio 0.14) [@b0030].

Diabetes is characterised, not only by hyperglycaemia, but also endothelial dysfunction and microcirculatory impairment [@b0045]. Microvascular disease (either retinopathy or nephropathy) is present in over one-third of newly-diagnosed patients with type-2 diabetes (T2D) [@b0050]. The consequences of endothelial dysfunction include dysregulation of vasodilation, fibrinolysis, and anti-aggregation -- classically leading to macrovascular disease - and may contribute to microvascular disease retinopathy, nephropathy and neuropathy [@b0050]. However, evidence of microvascular dysfunction in one organ is a marker of systemic injury. It is increasingly recognised that there are microvascular pulmonary complications of diabetes ('diabetic lung') [@b0055]. It has been suggested that reduced pulmonary diffusing capacity for carbon monoxide (DL~CO~) [@b0055], [@b0060] may be attributed to vascular injury of pulmonary capillaries related to diabetic microangiopathy [@b0055], [@b0065]. Importantly, the functional impairment was directly related to the degree of glucose control (glycated haemoglobin - HbA~1c~) and the presence of diabetic microvascular complications including retinopathy, neuropathy, and microalbuminuria in a sex-specific manner [@b0055]. The relationship of impaired gas exchange with diabetes was observed, even in those who had never smoked [@b0055]. In these individuals, the pulmonary microvasculature may be poorly prepared to meet the challenge of COVID-19 infection.

The Black, Asian and minority ethnic (BAME) community have suffered disproportionally from COVID-19. BAME, although only 13% of the United Kingdom population and a younger age distribution [@b0070], accounts for one third of all COVID-19 cases and 34% of critically-ill COVID-19 patients [@b0075], [@b0080]. The mechanisms underlying the disproportionate effect of COVID-19 infection on BAME patients remain incompletely understood. However, BAME groups have a disproportionally high prevalence of T2D [@b0085] and disparities have been observed in diabetes control, monitoring and presence of microvascular complications in the BAME, compared to white population [@b0090]. In this context, dysglycaemia (both HbA~1c~ and mean glucose) associating with adverse outcomes in COVID-19, may be surrogates for the presence and severity of underlying microvascular disease [@b0030]. The prevalence of prediabetes among adults is approximately 38% and 35%, in the United States [@b0085] and United Kingdom [@b0095] respectively. Prediabetes is also over-represented in BAME population. In the UK, the hazard ratio for prediabetes in South Asians was 1.67 (1.12--2.50) and for Blacks 1.45 (0.92--2.27), compared to the white population [@b0095]. Although it is alluring to think that people with prediabetes are protected from microvascular disease; early stages of retinopathy, nephropathy, and neuropathy have been reported in people with prediabetes, with a prevalence of up to 10% [@b0050], [@b0100].

Microvascular disease and endothelial dysfunction may underlie adverse outcomes in COVID-19 and may represent the pathophysiological key missing link that identifies susceptible populations and may require specific treatment. Analyses of data on patients with COVID-19 should include details of diabetes complications and age, to untangle the complex interaction between ethnicity, diabetes and COVID-19 outcomes.
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